Navigation Links
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
Date:6/28/2010

CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its success and I take this opportunity to thank Mr. Pierre Fabre, visionary founder, for having entrusted me with this important mission".

Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".

The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.

    About Pierre Fabre group :

    The Pierre Fabre Group, the second largest independent French
    pharmaceutical company and leader in the field of in-pharmacy
    dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
    staff, and generates a turnover of EUR 1.8 billion.

    In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
    R&D in four priority therapeutic areas in public health: oncology, central
    nervous system, dermatology, cardio-vascular/metabolism.

    To learn more about Pierre Fabre, please refer to
    http://www.pierre-fabre.com.

    Press Contact :

    Djamila Hazene-Kedjem
    djamila.hazene.kedjem@pierre-fabre.com
    +33(0)1-49-10-81-72 / +33(6)89-45-87-95



'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
5. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
6. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
7. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
8. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
9. Indevus Announces Submission of New Drug Application
10. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):